
GRI Bio, Inc. (NASDAQ:GRI – Free Report) – Research analysts at HC Wainwright reduced their FY2026 earnings per share estimates for GRI Bio in a report released on Monday, November 16th. HC Wainwright analyst M. Keller now anticipates that the company will post earnings of ($3.63) per share for the year, down from their prior forecast of ($3.36). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for GRI Bio’s current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for GRI Bio’s Q4 2026 earnings at ($0.73) EPS, FY2027 earnings at ($0.20) EPS and FY2028 earnings at ($0.16) EPS.
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GRI Bio in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $21.00.
Check Out Our Latest Stock Report on GRI Bio
GRI Bio Stock Down 3.5%
NASDAQ GRI opened at $1.35 on Wednesday. The firm’s 50-day moving average is $1.72 and its two-hundred day moving average is $2.04. GRI Bio has a 12 month low of $1.33 and a 12 month high of $64.12.
GRI Bio (NASDAQ:GRI – Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.15.
About GRI Bio
GRI Bio is a clinical-stage biotechnology company developing therapies for inflammatory, fibrotic and autoimmune diseases. Its research focuses on invariant natural killer T (iNKT) cells, a type of immune cell involved in regulating inflammation and immune responses. The company’s lead candidate, GRI-0621, is an oral investigational therapy being developed for idiopathic pulmonary fibrosis, a progressive lung disease. GRI Bio is also advancing other drug candidates that target iNKT-cell biology for potential use in immune-mediated conditions.
Read More
- Five stocks we like better than GRI Bio
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with MarketBeat.com's FREE daily email newsletter.
